Ibrutinib Plus R-CHOP for Younger Patients With DLBCL

New evidence suggests that adding the BTK inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of DLBCL.

The ASCO Post
Which New Therapeutics Are Generating Excitement at This Year’s ICML?

Dr Salles summarizes preclinical data on a histone deacetylase inhibitor investigated for T-cell lymphoma, as well as data on bispecific antibodies investigated for DLBCL.

IELSG30: Treating Primary Testicular DLBCL

Dr Annarita Conconi summarizes the results of the Phase II IELSG30 trial assessing R-CHOP, intravenous methotrexate, liposomal cytarabine, and scrotal irradiation in patients with primary DLBCL of the testis.


Sequencing Treatment Options in Primary Refractory DLBCL


Davies begins by outlining a specific patient case, caveats in the current treatment options for DLBCL, and the patterns of primary refractory DLBCL.

First-in-Human Trial of ALLO-501A in R/R Large B-cell Lymphoma

Dr Michael Tees discusses the first-in-human data of ALLO-501A, an allogeneic CAR-T product under investigation in relapsed/refractory large B-cell lymphoma in the ALPHA2 study.

R-CHOP Dose Intensity and Survival Outcomes in DLBCL

Chan Yoon Cheah, MBBS, discusses the results of a systematic review investigating the impact of R-CHOP dose intensity on survival outcomes in patients with DLBCL.

Outcomes of CAR-T Therapy in Patients With Refractory B-Cell Lymphoma

Dr Bruce Levine reports on the outcomes for refractory B-cell Lymphoma patients with CAR T-cell therapy.

Is Mosunetuzumab Safe and Effective for Elderly Patients With Untreated DLBCL?

Dr Olszewski reports the results of a phase I/II clinical trial of mosunetuzumab as a first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma.

Ibrutinib Therapy Prior to Tisa-Cel in R/R DLBCL

Dr Frederick Locke discusses the results of a Phase Ib safety trial of tisagenlecleucel in combination with ibrutinib, a BTK inhibitor, in R/R diffuse large B-cell lymphoma patients.

Changes in the Classification of DLBCL

Dr Andrew Davies discusses heterogeneity within diffuse large B-cell lymphoma and how molecular profiling of tumor clones can allow reclassification of the disease.

Alexander Study: CD19/22 Dual Targeting CAR T-Cell Therapy With Pembrolizumab in R/R DLBCL

During the ASCO Annual Meeting, the Lymphoma Hub speaks to Dr Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

CAR-T Moving Forwards for R/R DLBCL

Dr Anna Sureda gives an overview of first line therapies and the role of stem cell transplantation and CAR-T therapy in the treatment of DLBCL.

New Models for NHL Care: Innovative Therapy in FL and DLBCL

Dr Nathan H. Fowler, Dr Martin Dreyling, Dr Caron Jacobson and Dr Krish Patel discuss non-Hodgkin lymphoma in this CME activity titled Building New Management Models for NHL Care...

New Options When DLBCL Doesn’t Respond to Treatment

Linda Bohannon interviews Dr Kami Maddocks about the newest treatments for relapsed/refractory DLBCL.

Mosunetuzumab for Chemotherapy-Intolerant DLBCL

Dr Adam Olszewski shares the preliminary results of the ongoing Phase I/II trial assessing the safety and efficacy of mosunetuzumab in patients with DLBCL who are intolerant to chemotherapy.

ZUMA-9: Expanded Access Protocol and OOS Axicabtagene Ciloleucel in R/R DLBCL

Dr Frederick Locke outlines the results of the ZUMA-9 trial of out-of-specification or expanded access to axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B-cell lymphoma patients.

Real-World Efficacy & Safety Data: CAR-T in DLBCL

Dr Matthew Frigault comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory DLBCL including results from ZUMA-1, JULIET, and TRANSCEND studies.

Current Treatment Landscape of DLBCL

Dr Edmund Waller explores the current treatment landscape of DLBCL and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in various studies.

Bi-Specific Antibody - DLBCL and Follicular Lymphoma

Dr Joshua Brody discusses updates from ASH, highlighting DLBCL treatment. 

Looking Beyond R-CHOP in Diffuse B-Cell Lymphoma

Dr Farzanna Haffizulla interviews Dr Brad Kahl on looking beyond R-CHOP in diffuse b-cell lymphoma.


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)